title: Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting.
abstract: In light of current interest in recombinant human growth hormone (GH) as a treatment for fat distribution abnormalities, we retrospectively evaluated regional changes in fat and lean body mass in a subset of subjects who participated in randomized, double-blind, placebo-controlled trials of GH for treatment of wasting. Treatment with a pharmacologic dose of GH (0.1 mg/kg/day) resulted in significant and sustained increases in lean body mass and losses of fat in both the trunk and appendicular regions.
authors.affiliation: Department of Medicine, University of California, San Francisco, USA.
authors.forename: Viva W
authors.initials: VW
authors.lastname: Tai
authors.forename: Morris
authors.initials: M
authors.lastname: Schambelan
authors.forename: Heather
authors.initials: H
authors.lastname: Algren
authors.forename: Clara
authors.initials: C
authors.lastname: Shayevich
authors.forename: Kathleen
authors.initials: K
authors.lastname: Mulligan
mesh_terms: D000328:Adult; D002986:Clinical Trials as Topic; D005223:Fats / Q000378:metabolism*; D005260:Female; D015658:HIV Infections / Q000150:complications*; D019382:Human Growth Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008659:Metabolic Diseases / Q000188:drug therapy* / Q000209:etiology; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D005223:Fats; D011994:Recombinant Proteins; D019382:Human Growth Hormone